Explore Pharmaceutical Industry
We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical and biotechnology companies, and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Recently disclosed research collaborations include those with Servier, Daiichi Sankyo, Lundbeck, PhoreMost and Asahi Kasei Pharma, and we seek additional partnerships.
We also, have an extensive pipeline of partnered new chemical entities in pre-clinical and clinical development with Celgene, Corvus, CTI BioPharma, Cumulus Oncology, Servier and Verona Pharma, and we explore additional licensing opportunities for our currently unpartnered drug candidates.
Research Collaborations
We are involved in a number of research collaborations with major pharmaceutical and biotechnology companies, and academic partners. These range from early-stage research, establishing target tractability, to late-stage lead optimization programs. We value close coöperation with our collaborators to ensure that the combined strengths of the partners are most effectively deployed to deliver drug candidates. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success.
We have a strong, interdisciplinary and expert team.
We integrate fragment-based approaches, structural biology, biophysics, assay technology and molecular modeling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets. This requires a deep understanding of the techniques involved and a cautious interpretation of data; an approach grounded on two decades of developing and applying fragment-based lead discovery to challenging targets.
- Protein engineering, expression, and purification
- Structural biology – X-ray and NMR
- Biophysics – NMR/ SPR/ ITC/ MST/ DSF
- Cellular and biochemical assay development
